UBS upgrades Teva due to “attractive brand assets”
Swiss bank UBS has upgraded its recommendation for Israeli drugmaker Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to Buy from Neutral. UBs has also raised its price target for Teva from $11 to $13. The…